INZY - Inozyme gains after early Phase 1 data for lead candidate

Inozyme Pharma (INZY +15.1%), a biotech focused on rare diseases, is trading sharply higher in the morning hours Monday after announcing Phase 1/2 data for its lead candidate, INZ-701 in ENPP1 Deficiency, a condition with no approved therapies. The open-label trial is currently underway in North America and Europe involving adults with ENPP1 Deficiency. According to the early data in the Phase 1 portion of the trial, the first three patients showed “rapid, significant, and sustained increases” in PPi following a 0.2 mg/kg dose level of INZ-701, the company said, referring to a key biomarker indicating its therapeutic potential. “The data from the lowest dose cohort demonstrated that INZ-701 was able to rapidly and significantly increase PPi levels in these patients, with a potential for therapeutic benefit,” Chief Executive Axel Bolte noted, highlighting plans to disclose more data from the next dose levels. Inozyme (NASDAQ:INZY) shares have underperformed the broader biotech

For further details see:

Inozyme gains after early Phase 1 data for lead candidate